Global Checkpoint Inhibitors Market Trends, Strategies, And Opportunities 2021-2030 einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.
Biomarkers could help discriminate cancer therapy-associated kidney injury from other causes
A study by Mayo Clinic researchers published in
Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells.
Immune checkpoint inhibitors have improved the prognosis for patients with a wide range of malignancies including melanoma, non-small cell lung cancer and renal cancer. In some patients, this enhanced immune response may target kidney tissue, leading to acute kidney inflammation known as interstitial nephritis.
ESOU 2021: Must Read Papers in 2020: Renal Cancer
(UroToday.com) The final session at the 2021 European Association of Urology (EAU) Section of Oncological Urology (ESOU) Virtual Annual Meeting included a “must-read papers of 2020” session, with Dr. Riccardo Campi presenting the key papers in renal cell carcinoma (RCC). Dr. Campi took an exhaustive approach to assess renal cancer studies published in 2020, searching 17 journals, of which there were 949 records and 298 related to RCC. These papers were then screened and 74 studies were evaluated among seven research topics in kidney cancer. From there he selected must-read papers based on (i) originality, (ii) quality, (iii) clinical implications, and (iv) research implications. The majority of kidney cancer studies published in 2020 included localized kidney cancer (41.3%) and systemic therapies for metastatic renal cell carcinoma (20.8%):
ESOU 2021: Surgery in Detail - Key Points on Partial Nephrectomy: Ischemia vs No Ischemia
(UroToday.com) The first Renal Cancer session at this year’s European Association of Urology (EAU) Section of Oncological Urology (ESOU) 2021 virtual annual meeting focused on localized disease and was divided into two primary sections, the first focusing on key points in partial nephrectomy while the second examined approaches to larger renal masses. In the first mini-session examining key points in partial nephrectomy, Dr. Mottrie discussed considerations when considering ischemia versus no ischemia in robotic-assisted partial nephrectomy.
Dr. Mottrie began by highlighting data from a systematic review published in European Urology which, after including 91 studies performed between 2005 and 2014, concluded that 20-25 minutes represents the most accurate cut-off for clinically relevant ischemia. The authors also concluded that the use of no-ischemia or partial occlusive approaches may im